Bayer posts strong Q1 2026 results as Crop Science surge lifts earnings & outlook

Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros

Shilpa Medicare signs long-term CDMO pact with NXI Therapeutics to expand global biotech push

Shilpa will deliver end-to-end services including CMC development, process scale-up, GMP clinical supply, and commercial manufacturing support

Suven Life Sciences reaches 76% milestone in Phase 3 masupirdine trial for Alzheimer’s agitation

The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies

Merck to showcase 100+ oncology studies at 2026 ASCO meeting

Highlighting KEYTRUDA & expanding cancer pipeline

Edwards Lifesciences highlights 10-year data reinforcing durability of RESILIA tissue

Neuland Laboratories posts blockbuster FY26 performance

Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth

The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion

Pfizer scores landmark EU approval for hemophilia drug HYMPAVZI

The decision marks a significant expansion for Pfizer’s once-weekly injectable therapy

Revvity wins FDA clearance for total testosterone test

Roche wins CE mark for Alzheimer’s blood test that could transform early diagnosis

The test is designed to help clinicians either rule in or rule out amyloid pathology in patients showing signs of cognitive decline